Randomized Trial Backs HIF-2a Inhibition in Advanced RCC
MADRID — Treatment with the hypoxia-inducible factor 2α (HIF-2α) inhibitor belzutifan (Welireg) in advanced, heavily pretreated kidney cancer led to superior outcomes when compared with an older kinase inhibitor, a phase III trial demonstrated. Final progression-free survival (PFS) analysis showed a 26% reduction in disease progression or death with belzutifan versus everolimus (Afinitor), despite an […]